ERRα Expression in Bone Metastases Leads to an Exacerbated Antitumor Immune Response.


Journal

Cancer research
ISSN: 1538-7445
Titre abrégé: Cancer Res
Pays: United States
ID NLM: 2984705R

Informations de publication

Date de publication:
01 07 2020
Historique:
received: 13 11 2019
revised: 20 03 2020
accepted: 28 04 2020
pubmed: 6 5 2020
medline: 18 11 2020
entrez: 6 5 2020
Statut: ppublish

Résumé

Bone is the most common metastatic site for breast cancer. Although the estrogen-related receptor alpha (ERRα) has been implicated in breast cancer cell dissemination to the bone from the primary tumor, its role after tumor cell anchorage in the bone microenvironment remains elusive. Here, we reveal that ERRα inhibits the progression of bone metastases of breast cancer cells by increasing the immune activity of the bone microenvironment. Overexpression of ERRα in breast cancer bone metastases induced expression of chemokines CCL17 and CCL20 and repressed production of TGFβ3. Subsequently, CD8

Identifiants

pubmed: 32366476
pii: 0008-5472.CAN-19-3584
doi: 10.1158/0008-5472.CAN-19-3584
doi:

Substances chimiques

Biomarkers, Tumor 0
CCL17 protein, human 0
CCL20 protein, human 0
Chemokine CCL17 0
Chemokine CCL20 0
Receptors, Estrogen 0
TGFB3 protein, human 0
Transforming Growth Factor beta3 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2914-2926

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Mathilde Bouchet (M)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Alexandra Lainé (A)

University of Lyon-France.
Tumor Escape Resistance and Immunity Department, CRCL, INSERM 1052 CNRS 5286, Centre Léon Bérard, Labex DEVweCAN, Lyon, France.

Cyril Boyault (C)

Institute for Advanced Biosciences, UMR5209-INSERM1302, La Tronche, France.

Mathilde Proponnet-Guerault (M)

Institute for Advanced Biosciences, UMR5209-INSERM1302, La Tronche, France.

Emmanuelle Meugnier (E)

INSERMU1060-INRA-U1397, Lyon, France.

Lamia Bouazza (L)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Casina W S Kan (CWS)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Sandra Geraci (S)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Soumaya El-Moghrabi (S)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Hector Hernandez-Vargas (H)

Tumor Escape Resistance and Immunity Department, CRCL, INSERM 1052 CNRS 5286, Centre Léon Bérard, Labex DEVweCAN, Lyon, France.

Claire Benetollo (C)

University of Lyon-France.
INSERM-UMR5292 INSERM U1028, Lyon, France.

Yuji Yoshiko (Y)

Department of Calcified Tissue Biology, Hiroshima University, 1-2-3 Kasumi, Minami-ku, Hiroshima, Japan.

Martine Duterque-Coquillaud (M)

University of Lille, Institut Pasteur de Lille, CNRS-UMR9020-INSERM-UMR1277, Lille, France.

Philippe Clézardin (P)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France.
University of Lyon-France.

Julien C Marie (JC)

University of Lyon-France. edith.bonnelye@inserm.fr julien.marie@inserm.fr.
Tumor Escape Resistance and Immunity Department, CRCL, INSERM 1052 CNRS 5286, Centre Léon Bérard, Labex DEVweCAN, Lyon, France.

Edith Bonnelye (E)

INSERM-UMR1033, Labex DEVweCAN, Lyon, France. edith.bonnelye@inserm.fr julien.marie@inserm.fr.
University of Lyon-France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH